IN THE CLAIMS

Please cancel claims 1-10 and 15-16 without prejudice.

Please add claim 21, and amend claims 11-14 and 17-19 as follows:

1-10. (Canceled)

11. (Currently amended) A phosphoramidate compound formed from an hydroxy functional or amino functional drug ~~compound of~~having the ~~general~~ formula Drug-ZH_s said ~~prodrug being a~~ compound ~~of~~ having the formula:

$R_rCH_2OP(O)(Z\text{-Drug})NR(CH_2)_nX$

wherein:

R is C_1-C_4 alkyl or -$(CH_2)_nX$;

n is 4 or 5;

Z is O or N;

X is an electrophilic group capable of being nucleophilically displaced from its bonded carbon atom; and

~~halo is chloro, bromo or iodo; and~~

the group R_rCH_2- is a biologically labile ester forming group.

12. (Currently amended) The ~~prodrug~~ compound of claim 11 wherein the drug is an amino acid, ~~or~~ a biologically active peptide, or a peptidomimetic.

13. (Currently amended) The ~~method~~ compound of claim 12 wherein Drug-ZH is a peptidomimetic ~~of~~ having the formula:



wherein Z is O or N;

q and k are independently 1 or 0; and

B is H, amino, protected amino, or C_1-C_4 alkanoylamino.

14. (Currently amended) The ~~prodrug~~ compound of claim 11 wherein the drug is a biologically active nucleotide analog.

15-16. (Canceled)

17. (Currently amended) A pharmaceutical composition comprising a phosphoramidate compound formed from ~~a~~ an hydroxy functional or amino functional drug compound ~~of~~ having the ~~general~~ formula Drug-ZH_s said ~~prodrug being a~~ compound ~~of~~ having the formula:

$R_rCH_2OP(O)(Z\text{-Drug})NR(CH_2)_nX$

wherein

R is C_1-C_4 alkyl or -$(CH_2)_nX$;

n is 4 or 5;

Z is O or N;

X is an electrophilic group capable of being nucleophilically displaced from its bonded carbon atom; and

~~halo is chloro, bromo or iodo;~~

the group R_rCH_2- is a biologically labile ester forming group; and

a pharmaceutically acceptable carrier therefor.

18. (Currently amended) The pharmaceutical ~~compound~~ composition of claim 17 wherein Drug-ZH is an amino acid, ~~or~~ a biologically active peptide, or a peptidomimetic.

19. (Currently amended) The pharmaceutical composition of claim 18 wherein Drug-ZH is a peptidomimetic ~~of~~ having the formula:



wherein Z is O or N;

q and k are independently 1 or 0; and

B is H, amino, protected amino, or C_1-C_4 alkanoylamino.

20. (Original) The pharmaceutical composition of claim 17 wherein Drug-ZH is a nucleotide analog.

21. (New) The compound of claim 11 wherein R is methyl; n is 4; X is chloro; the group R_rCH_2- is a radical having the formula:



; and

Drug-ZH is a nucleotide analog having the formula:



,

wherein Z is oxygen.